ArticleAlzheimer disease and associated disorders
An Initial Empirical Operationalization of the Earliest Stages of the Alzheimer's Continuum.
Article in Alzheimer disease and associated disorders. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Do Perspectives Matter? Comparing Patient, Informant, and Clinician Subjective Cognitive Decline.medRxiv : the preprint server for health sciences · 2026Article
- Linking traditional and technological activities of daily living: Building modern, adaptable measures of daily functioning.Journal of the International Neuropsychological Society : JINS · 2025Article
- Cognitive dispersion and its functional relevance in behavioral variant frontotemporal dementia and prodromal behavioral variant frontotemporal dementia.Neuropsychology · 2024Article
- Recent Advances in Neuropsychological Test Interpretation for Clinical Practice.Neuropsychology review · 2024Review
- Clinical importance in Alzheimer's disease: effects of anchor agreement and disease severity.Aging clinical and experimental research · 2024Article
- Ecological validity of cognitive fluctuations in dementia with Lewy bodies.Journal of the International Neuropsychological Society : JINS · 2024Article
- The relationship between learning slopes and Alzheimer's Disease biomarkers in cognitively unimpaired participants with and without subjective memory concerns.Journal of clinical and experimental neuropsychology · 2023Article
- Dispersion-based cognitive intra-individual variability in dementia with Lewy bodies.Neuropsychology · 2022Article
- A Comparison of Operational Definitions for Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2022Observational
- Common Fatal Neurodegenerative Diseases Revisited: Beyond Age, Comorbidities, and Devastating Terminal Neuropathology There Is Hope With Prevention.Frontiers in neurology · 2022Article
- Empirically defining the preclinical stages of the Alzheimer's continuum in the Alzheimer's Disease Neuroimaging Initiative.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2021Article
- The Uniform Dataset 3.0 Neuropsychological Battery: Factor Structure, Invariance Testing, and Demographically Adjusted Factor Score Calculation.Journal of the International Neuropsychological Society : JINS · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThe Alzheimer's Continuum (AC) includes 2 preclinical stages defined by subjective cognitive complaints, transitional cognitive declines, and neurobehavioral symptoms. Operationalization of these stages is necessary for them to be applied in research.
methodsCognitively normal individuals with known amyloid biomarker status were selected from the National Alzheimer's Coordinating Center Uniform Data Set. Participants and their caregivers provided information on subjective cognitive complaints, neurobehavioral features, and objective cognitive functioning. PATIENTS: The sample included 101 amyloid positive (A+) and 447 amyloid negative (A-) individuals.
resultsRates of subjective cognitive complaints (A+: 34.90%, A-: 29.90%) and neurobehavioral symptoms (A+: 22.40%, A-: 22.40%) did not significantly differ between A+/- individuals. However, the frequency of transitional cognitive decline was significantly higher among A+ (38.00%) than A- participants (24.90%). We explored various empirical definitions for defining the early stages of the AC among A+ participants. Rates of classification into AC stage 1 versus AC stage 2 varied depending on the number of symptoms required: 57.40% versus 42.60% (1 symptom), 28.70% versus 71.30% (2 symptoms), and 6.90% versus 93.10% (all 3 symptoms).
conclusionThe presence of 2 of the proposed symptom classes to separate AC stage 2 from stage 1 seems to provide a good empirical balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.